Company Overview of Endo Pharmaceuticals Solutions Inc.
Endo Pharmaceuticals Solutions Inc. develops products to treat conditions in urology and endocrinology in the United States. The company’s approved products consist SANCTURA, a muscarinic receptor antagonist, and SANCTURA XR for the treatment of overactive bladder that are co-promoted with its partner Allergan, Inc.; VANTAS for treating advanced prostate cancer; SUPPRELIN LA for central precocious puberty; and DELATESTRYL for the treatment of hypogonadism. Its urology and endocrinology development portfolio contains multiple compounds, which comprise NEBIDO for hypogonadism; VALSTAR for bladder cancer; PRO 2000 for the prevention of infection by HIV and other sexually-transmitted diseases; t...
100 Endo Boulevard
Chadds Ford, PA 19317
Founded in 1988
Key Executives for Endo Pharmaceuticals Solutions Inc.
Chief Legal Officer, Executive Vice President and Secretary
Compensation as of Fiscal Year 2015.
Endo Pharmaceuticals Solutions Inc. Key Developments
Cipla Plans To Acquire US-Based Companies
Feb 19 15
Cipla Limited (BSE:500087) is reportedly in talks to acquire US-based companies. Sources indicated that Cipla is in talks to acquire companies with large manufacturing units in generics, respiratory and oncology spaces. The acquisition size is likely to be around $200-300 million. Cipla is said to be targeting Indigo Pharmaceuticals, Inc. and Endo Pharmaceuticals Solutions Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries